Nuzenio

Reclaim Phase Ii

Reclaim Phase Ii news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 4 latest news signals 4 publisher sources 100/100 entity strength

Latest news

Altimmune’s Pemvidutide Meets Phase II Endpoint in Alcohol Use Disorder Trial - TradingViewTradingView · Tue, 28 Jul 2026 14:04:17 GMTAltimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder - Yahoo FinanceYahoo Finance · Tue, 28 Jul 2026 07:00:00 GMTAltimmune, Inc. (ALT) Discusses Topline Results of RECLAIM Phase II Trial of Pemvidutide in Alcohol Use Disorder - Slideshow (NASDAQ:ALT) 2026-07-28 - Seeking AlphaSeeking Alpha · Tue, 28 Jul 2026 07:00:00 GMTUpdated: Altimmune’s GLP-1-based shot cuts drinking in patients with alcoholism - Endpoints NewsEndpoints News · Tue, 28 Jul 2026 07:00:00 GMT

Timeline

Tue, 28 Jul 2026 14:04:17 GMTAltimmune’s Pemvidutide Meets Phase II Endpoint in Alcohol Use Disorder Trial - TradingView
Tue, 28 Jul 2026 07:00:00 GMTAltimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder - Yahoo Finance
Tue, 28 Jul 2026 07:00:00 GMTAltimmune, Inc. (ALT) Discusses Topline Results of RECLAIM Phase II Trial of Pemvidutide in Alcohol Use Disorder - Slideshow (NASDAQ:ALT) 2026-07-28 - Seeking Alpha
Tue, 28 Jul 2026 07:00:00 GMTUpdated: Altimmune’s GLP-1-based shot cuts drinking in patients with alcoholism - Endpoints News

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Reclaim Phase Ii.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

4 distinct publisher/source names are currently connected to this entity page.